Physician
Oncology
Dr. Jeffrey R. Infante, MD
|
|
Give Review
Dr. Jeffrey R. Infante is an expert in the field of Oncology. He went to medical school at University of Florida College of Medicine. University of Florida College of Medicine has a rank of 43 in research and a 78 in primary care Doctor Jeffrey R. Infante, MD is also a published doctor. He has 79 paper published. The most recent paper is: [Radionuclide bone scanning in patients with breast carcinoma. Study of lesions by stages, locations and diagnostic assessment]. Doctor Jeffrey R. Infante, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced Cancer.
- ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid t...
- A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid Tumors.
- Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal Cancer.
- Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal Cancer.
- Molecular Pathways: Fatty Acid Synthase.
- A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258).
- Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
- Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic p...
- Phase 1b study of the oral gemcitabine 'Pro-drug' LY2334737 in combination with capecitabine in patients with advanced solid Tumors.
- A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid Tumors.
- A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid Tumors.
- Assessment of the Drug Interaction Potential and Single- and Repeat-Dose Pharmacokinetics of the BRAF Inhibitor Dabrafenib.
- Clinical impact of checkpoint inhibitors as novel Cancer therapies.
- Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid Tumors.
- Characteristics of pyrexia in BRAFV600E/K metastatic Melanoma patients treated with combined dabrafenib and trametinib in a phase 1/2 clinical trial.
- Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors.
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor.
- A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory m...
- Phase I dose-escalation studies of SNX-5422, an Orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.
- Targeting PI3 Kinase in Cancer.
- Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal Cell carcinoma.
- A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal Cell carcinoma.
- A randomised, double-blind, placebo-controlled trial of trametinib, an Oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adeno...
- Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
- A Phase I Dose Escalation Study of Oral c-MET Inhibitor Tivantinib (ARQ 197) in Combination with Gemcitabine in Patients with Solid Tumors.
- Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.
- Successful Treatment With Dabrafenib (GSK2118436) in a Patient With Ganglioglioma.
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine.
- Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma.
- Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid Tumors.
- Phase Ib trial of the Oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
- Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid Tumors.
- PARP inhibitors: pitfalls and promises.
- Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436).
- Everolimus in combination with paclitaxel and carboplatin in patients with metastatic Melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Resear...
- Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive Tumors.
- Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal Cancer: A randomized phase 2 study.
- Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid Tumors.
- A phase 1b study of trametinib, an Oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
- Unexpected renal toxicity associated with SGX523, a small molecule inhibitor of MET.
- A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid Tumors.
- First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement.
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor.
- Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic Melanoma.
- Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic Carcinoma of the pancreas: A Sarah Cannon Research Institute phase II...
- A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid Tumors.
- Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal Cancer.
- Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung Cancer.
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the Oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
- Phase 1 Results From a Study of Romidepsin in Combination With Gemcitabine in Patients With Advanced Solid Tumors.
- Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the Oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
- Phase II Study of Bevacizumab and Chemoradiation in the Preoperative or Adjuvant Treatment of Patients With Stage II/III Rectal Cancer.
- A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
- Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies.
- A phase I study of panobinostat in combination with gemcitabine in the treatment of solid Tumors.
- Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.
- Bevacizumab and everolimus in the treatment of patients with metastatic Melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.
- Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal Cancer.
- A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies.
- Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid Tumors.
- Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast Cancer.
- New markers of pancreatic Cancer identified through differential gene expression analyses: claudin 18 and annexin A8.
- Tumor COX-2 expression and prognosis of patients with resectable pancreatic Cancer.
- Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenoCarcinoma.
- Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid Tumors.
- [Radionuclide bone scanning in patients with breast Carcinoma. Study of lesions by stages, locations and diagnostic assessment].
- Serum levels and genetic variation of TGF-beta1 are not associated with Alzheimer''s disease.
- [NeuroLymphomatosis: diagnosis of extension and assessment of response to treatment with PET-CT].
- The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study.
- [CEA, CA 19.9 and CA 195 in patients with colorectal carcinoma. ROC Analysis].
- A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal Cancer and other...
- A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid Tumors.
- A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung Cancer.
- A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies.
- Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid Tumors.
- A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas Cancer.
- A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal Cell carcinoma.
Schools
University Of Florida College Of Medicine
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Johns Hopkins University -
University of Texas Southwestern Medical School -
University of Florida College of Medicine
Drug Facts
| NPI NUMBER | 1396848271 | |
| NPPES Provider LastName | INFANTE | |
| NPPES Provider FirstName | JEFFREY | |
| NPPES Provider ZIPCode | 372031632 | |
| NPPES Provider State | TN | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 560.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 54.0 | |
| Percent Opioid Claims | 9.64 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1396848271 |
| Last Name Of The Provider | INFANTE |
| First Name Of The Provider | JEFFREY |
| View All |
Similar Doctors
|
Dr. Howard A. Burris III, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Igor Puzanov, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Brent N. Rexer, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Natalie R. Dickson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David R. Spigel, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|